Companies / BOC Sciences / Romosozumab
BOC Sciences

Romosozumab | BOC Sciences

Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Romosozumab binds to and inhibits sclerostin, promoting the activation of the Wnt/_-catenin pathway that normally stimulates osteoblasts.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.